Comparing Global Payments (NYSE:GPN) & Solana (NASDAQ:HSDT)

Global Payments (NYSE:GPN) and Solana (NASDAQ:HSDT) are both finance companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends and valuation.

Insider and Institutional Ownership

89.8% of Global Payments shares are owned by institutional investors. Comparatively, 18.6% of Solana shares are owned by institutional investors. 0.6% of Global Payments shares are owned by company insiders. Comparatively, 14.4% of Solana shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Global Payments and Solana”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Global Payments	$7.71 billion	2.91	$1.40 billion	($2.98)	-28.46
Solana	$6.02 million	28.52	-$40.89 million	($30.32)	-0.09

Global Payments has higher revenue and earnings than Solana. Global Payments is trading at a lower price-to-earnings ratio than Solana, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Global Payments and Solana, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Global Payments	3	17	10	0	2.23
Solana	1	1	2	0	2.25

Global Payments presently has a consensus price target of $94.48, suggesting a potential upside of 11.40%. Solana has a consensus price target of $4.00, suggesting a potential upside of 40.85%. Given Solana’s stronger consensus rating and higher possible upside, analysts plainly believe Solana is more favorable than Global Payments.

Volatility & Risk

Global Payments has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500. Comparatively, Solana has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500.

Profitability

This table compares Global Payments and Solana’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Global Payments	-9.16%	13.80%	5.73%
Solana	-1,302.78%	-41.86%	-18.53%

Summary

Global Payments beats Solana on 8 of the 14 factors compared between the two stocks.

About Global Payments

Global Payments Inc. provides payment technology and software solutions for card, check, and digital-based payments in the Americas, Europe, and the Asia-Pacific. It operates through two segments, Merchant Solutions and Issuer Solutions. The Merchant Solutions segment offers authorization, settlement and funding, customer support, chargeback resolution, terminal rental, sales and deployment, payment security, and consolidated billing and reporting services. This segment also provides an array of enterprise software solutions that streamline business operations of its customers in various vertical markets; and value-added solutions and services, such as point-of-sale software, analytics and customer engagement, payroll and reporting, and human capital management. The Issuer Solutions segment offers solutions that enable financial institutions and retailers to manage their card portfolios through a platform; and commercial payments, account payables, and electronic payment alternatives solutions for businesses and governments. It markets its products and services through direct sales force, trade associations, agent and enterprise software providers, referral arrangements with value-added resellers, and independent sales organizations. The company was founded in 1967 and is headquartered in Atlanta, Georgia.

About Solana

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.